TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02990091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid
Description: LOVAZA is an FDA approved drug that is lawfully marketed in the United States by GlaxoSmithKline. There is no intent to use the results of this study to support a change in the labeling or the advertising of the drug. The highest dose administered for the study is the recommended prescribed dose of LOVAZA, therefore not creating greater risk. The patient population and route of administration will not significantly increase the risk associated with the use of the product. We will be using this drug under an IND exemption.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid
Description: LOVAZA is an FDA approved drug that is lawfully marketed in the United States by GlaxoSmithKline. There is no intent to use the results of this study to support a change in the labeling or the advertising of the drug. The highest dose administered for the study is the recommended prescribed dose of LOVAZA, therefore not creating greater risk. The patient population and route of administration will not significantly increase the risk associated with the use of the product. We will be using this drug under an IND exemption.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Safflower seed oil
Description: Safflower seed oil is a commonly used dietary supplement. It has been chosen to be used as a comparative to the LOVAZA because of its non-omega-3 fats. There will be no increased risk due to dosage, route of administration, or patient population.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Safflower seed oil
Description: Safflower seed oil is a commonly used dietary supplement. It has been chosen to be used as a comparative to the LOVAZA because of its non-omega-3 fats. There will be no increased risk due to dosage, route of administration, or patient population.
Study: NCT03662685

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Goeckerman Therapy
Description: The Goeckerman regimen consists of exposure to narrowband ultraviolet B (NB-UVB) light phototherapy and application of crude coal tar to the skin 5 days per week. The treatment will occur the UCSF outpatient skin treatment center for approximately 4-5 hours, 5 days a week for 6 weeks (total of 30 sessions). The treatment is consistent with the standard of care Goeckerman treatment protocol at UCSF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crude Coal Tar Only
Description: A topical medication consisting of crude coal tar will be applied to the psoriatic skin under plastic wrap occlusion for approximately up to 4-5 hours, 5 days a week for 6 weeks (total of 30 sessions), at the outpatient skin treatment center at UCSF.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy Only
Description: Light treatment with narrowband ultraviolet B (NB-UVB) phototherapy three days per week for 12 weeks at the UCSF Phototherapy Center per the standard UCSF phototherapy protocol, in which starting dose is based on the subject's Fitzpatrick skin type and gradually increased as tolerated. Each phototherapy treatment will last approximately from under 1 minute to less than 15 minutes.
Study: NCT04319380

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RTS,S/AS01
Description: One booster dose of RTSS/AS01 (June) in year 1 and 2.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RTS,S/AS01
Description: One booster dose of RTSS/AS01 (June) in year 1 and 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMC placebo
Description: Year 1 and 2 (2020/21) Four cycles of SMC placebo (July, August, September, October)
Study: NCT03277638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab at 7 days prior
Description: Pembrolizumab injections 7 days before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab at 14 days post
Description: Pembrolizumab injections 14 days after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab at 35 days post
Description: Pembrolizumab injections 35 days after surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Interstitial Thermotherapy
Description: surgical procedure to heat hard to reach tumors with a laser beam

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Interstitial Thermotherapy
Description: surgical procedure to heat hard to reach tumors with a laser beam

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Interstitial Thermotherapy
Description: surgical procedure to heat hard to reach tumors with a laser beam
Study: NCT03761017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lorigerlimab
Description: Bispecific DART protein binding PD-1 and CTLA-4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lorigerlimab
Description: Bispecific DART protein binding PD-1 and CTLA-4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lorigerlimab
Description: Bispecific DART protein binding PD-1 and CTLA-4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lorigerlimab
Description: Bispecific DART protein binding PD-1 and CTLA-4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lorigerlimab
Description: Bispecific DART protein binding PD-1 and CTLA-4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lorigerlimab
Description: Bispecific DART protein binding PD-1 and CTLA-4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lorigerlimab
Description: Bispecific DART protein binding PD-1 and CTLA-4
Study: NCT02428556

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facts only
Description: Communicate basic information about breakthrough drugs provided in FDA press release without using Breakthrough label

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: promising language
Description: Communicate basic information about breakthrough drugs provided in FDA press release, using language commonly used by FDA in describing breakthrough drugs (promising drug)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breakthrough only
Description: Communicate basic information about breakthrough drugs provided in FDA press release using Breakthrough label (similar to information found in FDA press releases)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: breakthrough with may warning
Description: Adding a tentative disclaimer (similar to that found on the FDA labels of some breakthrough designation drugs): Continued approval for this indication may be contingent upon verification and description of clinical trial benefit in confirmatory trials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: breakthrough with is warning
Description: Adding a more definitive disclaimer to minimize inaccurate inference from Breakthrough terminology: Continued approval for this indication is contingent upon verification and description of clinical trial benefit in confirmatory trials.
Study: NCT00309751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin 4 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 20 mg
Study: NCT01502813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline, Omega-3 Fatty Acids and Creatine
Description: Citicoline: 500 mg/day for 28 days Omega-3 Fatty Acids: 2 g/day for 28 days Creatine: 5 g/day for 28 days
Study: NCT02613403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3682B
Description: Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR) taken once daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3682B
Description: Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR) taken once daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3682B
Description: Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR) taken once daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3682B
Description: Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR) taken once daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3682B
Description: Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR) taken once daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 200 mg capsules, taken twice daily by mouth as part of a weight-based dosing regimen. Depending on participant body weight, total daily dose of Ribavirin may be 800, 1000, 1200 or 1400 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 200 mg capsules, taken twice daily by mouth as part of a weight-based dosing regimen. Depending on participant body weight, total daily dose of Ribavirin may be 800, 1000, 1200 or 1400 mg per day.
Study: NCT00733174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05194696

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Patients have to answer a questionnaire about their caffeine consumption habits during lifetime
Study: NCT02807857

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard care
Description: Patients will receive the treatment that their primary care physician has decided to prescribe for their disease
Study: NCT02115659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptolide-Containing Formulation
Description: Triptolide-Containing Formulation (1mg/kg/d) plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain, etc.
Study: NCT00778856

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand transplantation
Description: allotransplantation of deceased donor composite tissue (hand and forearm)
Study: NCT02493166

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dual task cost (cognitive-motor interference)
Description: comparing single versus dual task performance (on both motor and cognitive task)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dual task cost (cognitive-motor interference)
Description: comparing single versus dual task performance (on both motor and cognitive task)
Study: NCT04536766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Sleep Health Education
Description: The intervention comprehensively addresses poor sleep health behaviors. Personalized sleep health education will be delivered in two telephone sessions by Beds for Kids staff members. Sleep health information will consist of the following evidence-based pediatric sleep health behaviors: ensuring adequate sleep duration, developing a family bedtime routine, keeping a regular sleep schedule, avoiding caffeine, and eliminating electronics in the bedroom and at bedtime. The enhanced sleep health intervention sessions will also include individualized problem-solving and tailoring to meet the family's needs. Personalization will be accomplished via direct questions to families during the education phone call related to their own barriers to achieving healthy sleep habits and goals for optimal sleep.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Beds for Kids Standard Program
Description: The Beds for Kids program provides beds, bedding, and written healthy sleep education to families living at or below 100% of the federal poverty line and without an individual child bed to sleep in.
Study: NCT03918252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: Receive preoperative nivolumab, 240mg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: Receive preoperative nivolumab, 240mg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab Injection
Description: Receive preoperative nivolumab, 3mg/kg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) + ipilimumab 1mg/kg IV on Day -42 prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
Study: NCT03440645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family-oriented primary cardiovascular prevention
Description: An initial screening visit including a targeted history, physical exam, and investigations as per the Canadian Cardiovascular Society's recommendations for cardiovascular primary prevention. Counselling and informational handouts on improved cardiovascular risk factor and lifestyle habits. All family and household members, as well as the cardiovascular disease proband, are encouraged to attend and participate in all healthcare visits.
Study: NCT02440438

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples of 10 mL will be performed every 2 days from the first symptoms of CDI and until clinical recovery and/or hospital discharge
Study: NCT01147471

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: operative rib fixation
Description: Randomized subjects will be operated upon within 72 hours of ventilation (early fixation)to stabilize the stove-in segment using a rib fixation system.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operative rib fixation surgery
Study: NCT00056654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Description: 45 mg Intramuscular injection 6 month depot formulation
Study: NCT02667366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tel-PT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU and text messages
Study: NCT01463475

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone marrow aspirate
Description: A single bone marrow aspirate procedure is planned.
Study: NCT02067819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Oral Orthotic Treatment
Description: Active treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Orthotic Treatment
Description: After two weeks, this treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
Study: NCT01540305

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS was administered by means of a NEURO-MS (NEUROSOFT LTD®, Russia) with a focal 8-shaped 70 mm coil. Stimulation parameters were 1-Hz, 20-min trains (1200 pulses/day) at 100% of resting MT, once a day, 5 days a week, for 2 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: The sham treatment was performed using the Neurosoft ® sham coil. A metal plate placed inside this coil prevents the magnetic field from stimulating the cortex. This coil looks and sounds like an active coil.
Study: NCT03715985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVAX-01-CAF09b
Description: The personalised NPV-ds001 drug substance consists of multiple linear peptides (Pep-Ints) comprising natural L-amino acids dissolved in Dimethyl sulfoxide (DMSO) and 1 ml adjuvants (CAF09b) and 1,08 ml Tris buffer (25 ml).
Study: NCT03611088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo Position.
Description: The kangaroo position - the newborn is positioned in the adult's breasts, face down, should be dressed in light clothes and wrapped in a flexible cloth.
Study: NCT04561089

Intervention type: DIAGNOSTIC_TEST
Intervention: COVIDSeq Test
Description: The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19
Study: NCT03705663

Intervention type: BEHAVIORAL
Intervention: PrEP initiation
Description: Women who are interested in or who initiate PrEP will be followed in a prospective cohort to identify and populate the PrEP cascade for cis-gender, high risk women
Study: NCT00738400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil (Levitra, BAY38-9456)
Description: Vardenafil 10 mg tablets daily for 4 weeks, vardenafil 5 mg / 10 mg / 20 mg tablets for consecutive 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets daily for 4 weeks, placebo tablets daily for consecutive 4 weeks
Study: NCT03153306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin
Description: Two groups were formed at random for each fluid. In one group, 10ml/kg of 5% albumin was given over 1 hour (the bolus group), and in the other group, the same volume was given over 6 hrs (thecontinuous group)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin
Description: Two groups were formed at random for each fluid. In one group, 10ml/kg of 5% albumin was given over 1 hour (the bolus group), and in the other group, the same volume was given over 6 hrs (thecontinuous group)
Study: NCT03987698

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SHR-1210
Description: SHR-1210 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK cells
Description: CIK cells injection
Study: NCT03142490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture as a complementary therapy will be done in In vitro fertilization patients of the treatment group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Patients in both groups will be evaluated by 4 different questionnaires (before and after 8 to 12 weeks)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients in both groups will be evaluated by 4 different questionnaires (before and after 8 to 12 weeks)
Study: NCT01903109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cevimeline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cevimeline
Study: NCT03800368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Indoor cycling exercise intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Indoor cycling exercise intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-exercise
Description: Psycho-education
Study: NCT01094106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0,75%
Description: Postoperative wound infusion 2 ml/ h/ 48h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0,9%
Description: Postoperative wound infusion 2 ml/h/48h
Study: NCT00237224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study: NCT02993926

Intervention type: DRUG
Intervention: Enantone
Description: Enantone suspension for injection

Intervention type: DRUG
Intervention: GnRH agonist
Description: A non-Enantone GnRH agonist
Study: NCT00452114

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: In-Exsufflator Cough Assist Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Flutter Valve Device
Description: Active Comparator
Study: NCT02298998

Intervention type: OTHER
Intervention: Intervention
Description: Patients randomized into the intervention group will follow the European Urologic Association (EAU) surveillance guidelines for cystoscopy follow-ups during bladder cancer surveillance.

Intervention type: OTHER
Intervention: Control
Description: Patients randomized into the control group will follow the American Urologic Association (AUA) surveillance guidelines using cystoscopy ever 3 months for the first two years, and then every 6 months for 2 years.
Study: NCT06667648

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cupping session
Description: Each cupping session takes about 30-40 min and can be conducted in five steps. The first step includes primary suction. In this phase, the therapist allocates specific points or areas for cupping and disinfects the area, which located at the upper back (opposite to C7), Para spinal and below scapula. A cup with a suitable size is placed on the selected site and sucked the air inside the cup by manual suction. Then the cup was applied to the skin and left for a period of 3 to 5 min. The second step is about puncturing. Puncturing with a needle to get out of blood the third step is about suction and bloodletting. The cup is placed back on the skin using the similar procedure described above for 3 to 5 min. The fourth step includes the removal of the cup, followed by the fifth step which includes dressing the area after cleaning and disinfecting with FDA-approved skin disinfectant.
Study: NCT03972345

Intervention type: DRUG
Intervention: Norditropin® FlexPro®
Description: Patients will be treated with commercially available Norditropin® FlexPro® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.
Study: NCT02511184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: To test 3 dose levels of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: To test pembrolizumab at 200 mg every 3 weeks in combination with crizotinib at 3 dose levels.